摘要
目的 分析国家重点监控药品目录(以下简称“国控”)中的质子泵抑制剂(PPI)和抗菌药物在国家药品集中带量采购(以下简称“国采”)前后的使用情况,拟为医院药事管理与临床用药提供优化建议。方法 对某康复三级专科医院的抗菌药物6个品种和PPI2个品种在国采政策实施前后各一年的药品使用数据进行分析,统计其价格降幅、计算药品用药频度(DDDs)、日均治疗费用(DDC)、实际节省费用、节省费用率、日费用比、国采完成度等指标,评估分析国采政策实施情况。结果 国采政策实施后,中选药物的价格均不同幅度下降,平均降幅75%。除注射用奥美拉唑和注射用美罗培南外,其余6个品种的药品使用量均较前增加,但药品使用金额却整体降低、降幅明显,8个品种的药品总节省费用高达75.64万元。此外,国采药品的完成度均较高。结论 国采政策的实施,显著降低了药品费用,切实减轻了患者用药负担,减少医保资金支出。但仍需警惕部分同属国控目录中的药物用药合理性,在国采政策执行过程中应有的放矢,同时加强合理用药宣教和监控,避免出现不合理使用的风险。
Objective To analyze the use of proton pump inhibitors and antimicrobials in the national key monitoring drug list before and after the National Centralized Drug Procurement(referred to as"NCDP"),in order to provide optimization suggestions for hospital pharmaceutical management and clinical drug use.Methods The drug use data of 6 varieties of antibiotics and 2 varieties of proton pump inhibitors in a rehabilitation tertiary specialized hospital were analyzed one year before and after the implementation of NCDP policy.The price reduction,DDDs,DDC,actual cost saving,cost saving rate,daily cost ratio,and completion degree of national procurement were calculated to evaluate and analyze the implementation effect.Results After the implementation of NCDP,the prices of selected drugs decreased in different amplitude with an average reduction of 75%.In addition to omeprazole for injection and meropenem for injection,the use of the remaining 6 drugs increased,but the overall amount of money spent on drugs decreased significantly.The total cost savings of 8 varieties of drugs was as high as 756500 yuan.In addition,the completion degree of national drugs was high.Conclusion The implementation of NCDP can significantly reduce the cost of drugs,effectively reduce the burden of drugs for patients and reduce the expenditure of medical insurance funds.However,it is still necessary to be vigilant about the rationality of drug use of some drugs in the national key monitoring drug list,and it should be targeted in the implementation process of NCDP,while strengthening the education and monitoring of rational drug use to avoid the risk of irrational use.
作者
曹玲娟
柯柳娴
周子健
李尚
CAO Lingjuan;KE Liuxian;ZHOU Zijian(Department of Pharmacy,Guangdong Work Injury Rehabilitation Hospital,Guangzhou 510440,China)
出处
《中国处方药》
2025年第24期63-67,共5页
Journal of China Prescription Drug
基金
广东省卫生经济学会科研项目(2024-WJMF-43)。
关键词
国家药品集中带量采购
质子泵抑制剂
抗菌药物
康复三级医院
国家重点监控药品
National Centralized Drug Procurement
Proton pump inhibitor
Antimicrobial drug
Rehabilitation tertiary hospital
National key monitoring drug
